NASDAQ: ALKS | Healthcare / Biotechnology / Ireland |
28.03 | +0.1900 | +0.68% | Vol 1.22M | 1Y Perf 20.99% |
Oct 4th, 2023 16:00 DELAYED |
BID | 27.54 | ASK | 29.03 | ||
Open | 27.92 | Previous Close | 27.84 | ||
Pre-Market | - | After-Market | 28.03 | ||
- - | - -% |
Target Price | 31.20 | Analyst Rating | Moderate Buy 2.14 | |
Potential % | 11.31 | Finscreener Ranking | ★★+ 47.99 | |
Insiders Trans % 3/6/12 mo. | -100/-88/-68 | Value Ranking | ★★★ 50.61 | |
Insiders Value % 3/6/12 mo. | -100/-100/-96 | Growth Ranking | ★ 38.60 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-96 | Income Ranking | — - | |
Price Range Ratio 52W % | 52.51 | Earnings Rating | Strong Buy | |
Market Cap | 4.67B | Earnings Date | 1st Nov 2023 | |
Alpha | -0.01 | Standard Deviation | 0.11 | |
Beta | 0.60 |
Today's Price Range 27.6628.21 | 52W Range 21.7533.71 | 5 Year PE Ratio Range -33.90-17.60 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -0.46% | ||
1 Month | -3.97% | ||
3 Months | -6.85% | ||
6 Months | -4.56% | ||
1 Year | 20.99% | ||
3 Years | 72.39% | ||
5 Years | -37.17% | ||
10 Years | -13.27% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -6.25 | |||
ROE last 12 Months | -13.10 | |||
ROA (5Y Avg) | -3.69 | |||
ROA last 12 Months | -7.11 | |||
ROC (5Y Avg) | -8.19 | |||
ROC last 12 Months | -8.32 | |||
Return on invested Capital Q | -4.27 | |||
Return on invested Capital Y | 0.15 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 2.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-34.80 | ||||
4.27 | ||||
5.32 | ||||
86.70 | ||||
-575.10 | ||||
0.31 | ||||
4.93 | ||||
6.35 | ||||
4.28B | ||||
Forward PE | 19.05 | |||
PEG | -1.69 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.80 | ||||
2.20 | ||||
0.27 | ||||
0.39 | ||||
-12.60 | ||||
Leverage Ratio | 1.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
46.50 | ||||
-11.90 | ||||
-4.90 | ||||
-10.70 | ||||
-16.11 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
807.12M | ||||
4.91 | ||||
1.38 | ||||
6.75 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | 0.28 | 0.38 | 35.71 |
Q01 2023 | -0.19 | -0.10 | 47.37 |
Q04 2022 | -0.10 | -0.02 | 80.00 |
Q03 2022 | -0.13 | -0.14 | -7.69 |
Q02 2022 | -0.12 | -0.08 | 33.33 |
Q01 2022 | -0.14 | 0.01 | 107.14 |
Q04 2021 | -0.03 | 0.13 | 533.33 |
Q03 2021 | -0.05 | -0.02 | 60.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | 0.31 | 82.35 | Positive |
12/2023 QR | 0.40 | 53.85 | Positive |
12/2023 FY | 0.94 | 51.61 | Positive |
12/2024 FY | 1.47 | -18.33 | Negative |
Next Report Date | 1st Nov 2023 |
Estimated EPS Next Report | 0.31 |
Estimates Count | 4 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.22M |
Shares Outstanding | 166.56K |
Shares Float | 165.36M |
Trades Count | 13.54K |
Dollar Volume | 34.07M |
Avg. Volume | 1.48M |
Avg. Weekly Volume | 1.45M |
Avg. Monthly Volume | 1.35M |
Avg. Quarterly Volume | 1.65M |
Alkermes plc (NASDAQ: ALKS) stock closed at 28.03 per share at the end of the most recent trading day (a 0.68% change compared to the prior day closing price) with a volume of 1.22M shares and market capitalization of 4.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2245 people. Alkermes plc CEO is Richard F. Pops.
The one-year performance of Alkermes plc stock is 20.99%, while year-to-date (YTD) performance is 7.27%. ALKS stock has a five-year performance of -37.17%. Its 52-week range is between 21.75 and 33.71, which gives ALKS stock a 52-week price range ratio of 52.51%
Alkermes plc currently has a PE ratio of -34.80, a price-to-book (PB) ratio of 4.27, a price-to-sale (PS) ratio of 5.32, a price to cashflow ratio of 86.70, a PEG ratio of -1.69, a ROA of -7.11%, a ROC of -8.32% and a ROE of -13.10%. The company’s profit margin is -16.11%, its EBITDA margin is -4.90%, and its revenue ttm is $807.12 Million , which makes it $4.91 revenue per share.
Of the last four earnings reports from Alkermes plc, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.31 for the next earnings report. Alkermes plc’s next earnings report date is 01st Nov 2023.
The consensus rating of Wall Street analysts for Alkermes plc is Moderate Buy (2.14), with a target price of $31.2, which is +11.31% compared to the current price. The earnings rating for Alkermes plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alkermes plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alkermes plc has a Sell technical analysis rating based on Technical Indicators (ADX : 8.87, ATR14 : 0.72, CCI20 : -152.46, Chaikin Money Flow : -0.01, MACD : -0.27, Money Flow Index : 30.95, ROC : -5.95, RSI : 37.41, STOCH (14,3) : 4.73, STOCH RSI : 0.00, UO : 44.56, Williams %R : -95.27), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alkermes plc in the last 12-months were: Blair C. Jackson (Option Excercise at a value of $0), Blair Curtis Jackson (Option Excercise at a value of $0), Brown Iain (Option Excercise at a value of $0), Cato T. Laurencin (Sold 0 shares of value $-124 911 ), Cato T. Laurencin (Sold 5 438 shares of value $172 220 ), Christian Todd Nichols (Option Excercise at a value of $401 123), Christian Todd Nichols (Sold 27 134 shares of value $784 987 ), Craig C. Hopkinson (Option Excercise at a value of $0), Daglio David (Sold 0 shares of value $0 ), David A. Daglio (Buy at a value of $815 735), David Joseph Gaffin (Option Excercise at a value of $0), Gaffin David (Option Excercise at a value of $0), Hopkinson Craig (Option Excercise at a value of $0), Iain M. Brown (Option Excercise at a value of $0), Landine Michael (Option Excercise at a value of $0), Mckeon Brian (Sold 0 shares of value $0 ), Michael J. Landine (Option Excercise at a value of $0), Pops Richard (Option Excercise at a value of $0), Richard F. Pops (Option Excercise at a value of $0), Wysenski Nancy (Option Excercise at a value of $1 284 113), Wysenski Nancy (Sold 41 250 shares of value $1 288 650 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
CEO: Richard F. Pops
Telephone: +353 17728000
Address: 1 Burlington Road, Dublin D04 C5Y6, , IE
Number of employees: 2 245
Mon, 24 Jul 2023 08:30 GMT Analysts Top Healthcare Picks: Alkermes (ALKS), CymaBay Therapeutics (CBAY)
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.